Welcome to our dedicated page for Envoy Medical SEC filings (Ticker: COCHW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This Envoy Medical, Inc. (COCHW) filings page provides access to the company’s SEC disclosures, including current reports on Form 8-K that describe material events, securities offerings, and other significant developments. Envoy Medical is a hearing health company focused on medical technologies for hearing loss, with a single reportable segment related to hearing and revenue from Esteem FI-AMEI implants and replacement components.
Key filing types for Envoy Medical, Inc. include current reports on Form 8-K that outline material definitive agreements, unregistered sales of equity securities, and other events. Recent 8-K filings describe a securities purchase agreement for a registered direct offering of Class A common stock, a concurrent private placement of warrants, and the issuance of placement agent warrants. These documents detail purchase prices, warrant exercise terms, ownership limitations, lock-up periods, and restrictions on variable rate transactions.
Envoy Medical’s filings also reference an effective shelf registration statement on Form S-3 and obligations to file a registration statement on Form S-1 to register the resale of shares issuable upon exercise of certain warrants. For investors tracking warrant activity, the filings describe redeemable warrants trading under the COCHW symbol on The Nasdaq Stock Market LLC, as well as private and placement agent warrants issued in connection with offerings.
With AI-powered tools layered on top of these filings, users can quickly identify the core terms of Envoy Medical’s financing transactions, understand the structure of its warrant instruments, and see how registration rights and stockholder approval requirements are defined. Real-time updates from EDGAR, combined with AI-generated highlights, help clarify long-form disclosures so readers can focus on the provisions that matter most for Envoy Medical, Inc.’s capital structure and hearing-focused business.
Envoy Medical, Inc. files a prospectus supplement describing a securities offering and related risk factors. The company lists numerous operational and industry risks including regulatory uncertainty for medical devices, potential product design changes, supplier and manufacturing disruptions, reimbursement policy shifts, competition and alternative therapies, capital needs and financing availability, intellectual property risks, legal and regulatory proceedings, and catastrophic events. The prospectus also details planned uses of proceeds to advance Acclaim CI clinical development, pursue additional regulatory approvals, build commercial infrastructure, rely on third-party suppliers, expand intellectual property, and hire personnel. The filing discloses potential dilution from various warrants, options and convertible preferred shares (examples: 14,166,666 Public Warrant shares; 3,104,511 Meteora Warrant shares; 3,588,406 shares on conversion of Series A Preferred; and equity incentive plan options). It incorporates multiple prior reports by reference.
The company has filed a prospectus supplement to suspend its at-the-market stock offering program. Under the existing At The Market Offering Agreement with Roth Capital Partners, it had previously sold 174,012 shares of Class A Common Stock for aggregate gross proceeds of $266,060.
The supplement suspends the ATM program and the continuous offering under the related prospectuses effective on September 22, 2025, and no further sales can occur unless a new prospectus supplement is filed, although the ATM Agreement itself remains in force. The Class A Common Stock trades on the Nasdaq Capital Market under the symbol COCH, with a last reported sale price of $1.31 per share on September 19, 2025. The filing also notes that sales under Form S-3 are limited by the one-third public float cap when non-affiliate equity market value is under $75,000,000.
Envoy Medical, Inc. filed a current report to disclose that it has received a European patent titled “Implantable Cochlear System with Integrated Components and Lead Characterization.” This patent relates to the company’s implantable cochlear system technology.
The company announced the patent in a press release dated September 19, 2025, which is included as Exhibit 99.1 to the report and incorporated by reference.